Illumina Inc. Reaffirms Earnings Guidance for the Fourth Quarter of 2011; Post Pones its Fourth Quarter and Fiscal Year 2011 Earnings Release Date
January 27, 2012 at 10:13 am
Share
Illumina Inc. reaffirmed earnings guidance for the fourth quarter of 2011. For the quarter, the company estimates revenue of approximately $250 million and pro forma earnings of $0.34 per share.
The company announced that it will postpone its previously scheduled fourth quarter and fiscal year 2011 earnings announcement and related conference call with analysts, investors, and other interested parties. The company expects to issue fourth quarter and 2011 full year financial results concurrent with the board's completion of its review of Roche's unsolicited tender offer and the issue of its recommendation.
Illumina, Inc. specializes in the development, manufacturing and marketing of integrated systems for the analysis of genetic variation and biological function. The group's products are for genomic research centers, pharmaceutical companies, university institutions, clinical research organizations, and biotechnology companies. Net sales break down by source of income as follows:
- product sales (84.1%): tools and instruments for sequencing, genotyping, genetic expression, etc.;
- sales of services (15.9%).
Net sales are distributed geographically as follows: the United States (52.4%), Americas (3.6%), Europe (25.3%), Asia/Pacific/Middle East/Africa (10.2%) and China/Taiwan/Hong Kong (8.5%).
ILLUMINA, INC. 
